Adagene to Participate in Two Upcoming Investor Conferences
Globe Newswire (Tue, 12-May 8:30 AM ET)
Globe Newswire (Fri, 17-Apr 4:01 PM ET)
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Globe Newswire (Tue, 14-Apr 7:00 AM ET)
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Globe Newswire (Thu, 2-Apr 7:10 AM ET)
Globe Newswire (Thu, 2-Apr 7:01 AM ET)
Globe Newswire (Thu, 2-Apr 7:00 AM ET)
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 1-Apr 5:00 PM ET)
Globe Newswire (Tue, 17-Mar 4:35 PM ET)
Adagene's $74.5M Cash Reserves Pave Way for 2026 Clinical Milestones and New Collaborations
Market Chameleon (Fri, 23-Jan 6:49 AM ET)
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Adagene - Ads Each Representing 1.25 trades on the NASDAQ stock market under the symbol ADAG.
As of May 14, 2026, ADAG stock price declined to $3.66 with 2,085 million shares trading.
ADAG has a beta of 0.18, meaning it tends to be less sensitive to market movements. ADAG has a correlation of 0.00 to the broad based SPY ETF.
ADAG has a market cap of $241.83 million. This is considered a Small Cap stock.
Last quarter Adagene - Ads Each Representing 1.25 reported $8 million in Revenue and -$.24 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.37.
In the last 3 years, ADAG traded as high as $4.75 and as low as $1.10.
The top ETF exchange traded funds that ADAG belongs to (by Net Assets): PGJ.
ADAG has outperformed the market in the last year with a return of +112.8%, while the SPY ETF gained +28.7%. In the last 3 month period, ADAG beat the market returning +12.6%, while SPY returned +10.0%. However, in the most recent 2 weeks ADAG has underperformed the stock market by returning +3.1%, while SPY returned +5.1%.
ADAG support price is $3.49 and resistance is $3.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAG shares will trade within this expected range on the day.